公开(公告)号：US11058754B2

公开(公告)日：2021-07-13

申请号：US16915465

申请日：2020-06-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10532091B1

公开(公告)日：2020-01-14

申请号：US16507375

申请日：2019-07-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/395 ,  A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12121572B2

公开(公告)日：2024-10-22

申请号：US17502185

申请日：2021-10-15

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sarah Kutscher

IPC: A61K39/00 ,  A61K35/17 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  A61K35/12 ,  A61K51/10 ,  C07K7/08 ,  G01N33/68

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C12N5/0636 ,  C12N15/115 ,  A61K2035/124 ,  A61K39/00111 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K51/1057 ,  C07K7/08 ,  C07K2317/70 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/998 ,  G01N33/6803

Abstract: A peptide consists of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53), an adjuvant, and a pharmaceutically acceptable carrier.

公开(公告)号：US12097248B2

公开(公告)日：2024-09-24

申请号：US17508230

申请日：2021-10-22

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sarah Kutscher

IPC: A61K39/00 ,  A61K35/17 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  A61K35/12 ,  A61K51/10 ,  C07K7/08 ,  G01N33/68

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C12N5/0636 ,  C12N15/115 ,  A61K2035/124 ,  A61K39/00111 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K51/1057 ,  C07K7/08 ,  C07K2317/70 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/998 ,  G01N33/6803

Abstract: A peptide consists of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56), an adjuvant, and a pharmaceutically acceptable carrier.

公开(公告)号：US12076381B2

公开(公告)日：2024-09-03

申请号：US17576185

申请日：2022-01-14

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

CPC classification number: A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/5748 ,  G01N33/6848 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2310/16 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N2570/00 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11826409B2

公开(公告)日：2023-11-28

申请号：US17320938

申请日：2021-05-14

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68

CPC classification number: A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/5748 ,  G01N33/6848 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2310/16 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N2570/00 ,  G01N2800/52

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11786583B2

公开(公告)日：2023-10-17

申请号：US17245918

申请日：2021-04-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sarah Kutscher

IPC: A61K39/00 ,  A61K38/04 ,  C07K7/06 ,  C07K7/00 ,  A61K35/17 ,  C07K16/18 ,  G01N33/68 ,  C07K14/435 ,  C07K7/08 ,  A61K51/10 ,  A61K35/12 ,  C12N5/0783 ,  C12N15/115 ,  C07K14/725 ,  C07K14/74

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K14/435 ,  C07K16/18 ,  G01N33/6803 ,  A61K39/00111 ,  A61K51/1057 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K7/08 ,  C07K14/7051 ,  C07K14/70539 ,  C07K2317/70 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2501/998

Abstract: A peptide consists of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6), an adjuvant, and a pharmaceutically acceptable carrier.

公开(公告)号：US11779638B2

公开(公告)日：2023-10-10

申请号：US17853334

申请日：2022-06-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sarah Kutscher

IPC: C07K7/00 ,  A61K35/17 ,  A61K39/00 ,  A61K38/04 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  A61K51/10 ,  A61K35/12

CPC classification number: A61K39/00111 ,  A61K35/17 ,  A61K38/04 ,  A61K39/0011 ,  A61K51/1057 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C12N5/0636 ,  C12N15/115 ,  G01N33/6803 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K2317/70 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/998

Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214), in which the peptide is in a complex with an MHC molecule.

公开(公告)号：US11672848B2

公开(公告)日：2023-06-13

申请号：US17852623

申请日：2022-06-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sarah Kutscher

IPC: A61K35/17 ,  A61K39/00 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  A61K51/10 ,  A61K35/12

CPC classification number: A61K39/00111 ,  A61K35/17 ,  A61K38/04 ,  A61K39/0011 ,  A61K51/1057 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C12N5/0636 ,  C12N15/115 ,  G01N33/6803 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K2317/70 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/998

Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of ALVEQGFTV (SEQ ID NO: 5), in which the peptide is in a complex with an MHC molecule.

公开(公告)号：US11559573B2

公开(公告)日：2023-01-24

申请号：US17728756

申请日：2022-04-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni Weinschenk ,  Andrea Mahr ,  Jens Fritsche ,  Phillip Mueller ,  Anita Wiebe ,  Sarah Kutscher

IPC: A61K35/17 ,  A61K39/00 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  A61K51/10 ,  A61K35/12

Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.